Speaker illustration

Doctor Amit Khera

Verve Therapeutics, Cambridge (United States of America)

Member of:

European Society of Cardiology

An in vivo CRISPR base editing therapy to inactivate the ANGPTL3 gene: nomination of a development candidate for VERVE-201

Event: ESC Congress 2022

Topic: Gene Therapy, Cell Therapy

Session: RNA and gene therapy of vascular diseases

Thumbnail

This platform is supported by

logo Novo Nordisk